Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever Clinical Trial

Official title:

Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02948933
• Other study ID #: DNG15
• Secondary ID: U1111-1143-8608
• Status: Active, not recruiting
• Start date: December 14, 2016
• Est. completion date: July 1, 2024

Study information

• Verified date: January 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate the safety profile of Dengvaxia® when used in the real-world immunization setting

Primary Objective:

• To measure the incidence of selected adverse events (AEs) and serious AEs (SAEs) occurring over a period of six (6) months after each Dengvaxia® dose administration;

• To quantify the association between Dengvaxia® and each of the selected AEs and SAEs for which a risk window after vaccination can be defined, using estimates of relative risk

• To monitor the occurrence and frequency of hospitalized dengue disease as well as any other SAEs leading to hospitalization or death, including new and previously unrecognized SAEs, following Dengvaxia® administration on a longer term (up to 5 years after the first Dengvaxia® dose administration.

Secondary objectives:

• To identify risk factors for hospitalized dengue disease (severe or not) among subjects vaccinated with Dengvaxia®;

• To describe the frequency of hospitalized dengue disease and/or other SAEs or selected AEs according to the number of Dengvaxia® doses and/or interval between doses.

Description:

This is a prospective multi-national non-interventional study that includes two components of Cohort Event Monitoring (i) Short-term safety surveillance with a follow-up of 6 months after each Dengvaxia® dose administration and (ii) a long-term safety surveillance with a follow-up of five years after the first dose.

No vaccine will be provided as part of this study.

Study population will be identified in a convenient sample of sites as representative as possible of vaccination centers in each country. Subjects who received their first dose of Dengvaxia® at participating sites during the recruitment period and who meet the eligibility criteria will be asked to participate. After enrollment, vaccinees will be contacted periodically by telephone, e-mail, or Short Message Service (SMS) during follow-up for the identification of outcomes and Dengvaxia® vaccination status.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30000
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Years and older

Eligibility

Inclusion Criteria:

• Subjects who received the first dose of Dengvaxia® across all age groups, even if vaccination was given outside of local specific label indications or recommendations

• Informed consent form (ICF) or Assent form (AF) has been signed and dated by the subject (based on local regulations), and/or ICF has been signed and dated by the parent(s) or another legal acceptable representative (and by an independent witness if required by local regulations)

• Subjects for whom a telephone contact or an e-mail address is available.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Dengue
• Dengue Fever
• Dengue Hemorrhagic Fever
• Fever
• Hyperthermia
• Severe Dengue

Locations

Country	Name	City	State
Mexico	Investigational Site 2008-001	Cuernavaca
Mexico	Investigational Site 2011-001	Guerrero
Mexico	Investigational Site 2007-001	Mérida
Mexico	Investigational Site 2001-001	Mexico
Mexico	Investigational Site 2002-001	Monterrey
Mexico	Investigational Site 2003-001	Puerto Vallarta
Mexico	Investigational Site 2004-001	Veracruz
Mexico	Investigational Site 2006-001	Villahermosa
Mexico	Investigational Site 2010-001	Zapopan

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Countries where clinical trial is conducted

Brazil,  Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects with selected adverse events leading to a medical consultation, emergency room visit or hospitalization occurring during the short term surveillance period of 6 months after each dose of Dengvaxia®		6 months post-vaccination
Primary	Percentage of subjects hospitalized with dengue disease (regardless of severity and laboratory confirmation of diagnosis) after each dose of Dengvaxia®.		6 months post-vaccination
Primary	Percentage of subjects with any other serious adverse events (SAEs) occurring during the short term surveillance, and SAEs leading to hospitalization or death occurring during the long term surveillance		Up to 5 years post-vaccination

External Links

•   Related Info
•   Related Info